Sei Lee
speaker
547 appearances
9 recordings
1 series
first heard Feb 2017
last heard Oct 2022
Sei Lee’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
Oh yeah.
So the time to benefit page is trying to make the mortality indexes link more closely to the time to benefit.
So we have a list of various um interventions like uh hospice referral, like uh more intensive treatment for blood pressure, treatment for more intensive treatment for diabetes, for dysglycemia, uh hyperglycemia, um, uh statins, uh, bisphosphonates.
All of these different preventive medications, which uh we highlight the time to benefit.
And so that if somebody's uh estimated uh life expectancy is greater than the time to benefit, then that rec then that intervention would be recommended.
Whereas if the somebody's uh life expectancy is less than the time to benefit, then that uh intervention would generally not be recommended.
Yeah, I mean I think there's the the Hemingway quote about all stories continued long enough end in death.
And he is no true storyteller who will keep that from you.
Kind of similarly, I've I've made the remark to various uh in various forums to trainees about how, yeah, a survival model, uh, if you're going to go out 150 years, the survival model is going to be pretty boring because everyone is going to die.
And the only factor that really is going to matter at that stage is going to be age.
Um, I think fundamentally I will say that I think Dr.
Fitzgerald's comment has not won the day, uh, because increasingly what we're seeing is more and more clinical decisions that are tied to prediction.
And so the most common uh the two examples that I would talk about are treatment for um osteoporosis that is um
That hinges on the 10-year risk of fracture and then treatment for hyperlipidemia that hinges on predicted 10-year cardiovascular uh events.
And so the idea here is that.
Generally, the risks of bad things like side effects are pretty constant throughout the population.
And then so if you try to treat people at very low risk of disease, then their risk of the side effects may actually be higher than their risk of avoiding that disease.
Whereas if you treat people at high risk of the disease, their chances of benefit are going.
to be much higher than their chances of side effects.
And so this is all about trying to make sure that we are identifying people at high enough risk of the bad thing that we're trying to prevent so that they're more likely to benefit than be harmed by what we're doing to them.
Showing 41–60 of 547 · page 3 of 28
← Previous
Next →